Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

MorphoSys AG buy efeu

Start price
€22.29
09.08.22 / 50%
Target price
€28.00
09.08.23
Performance (%)
24.14%
End price
€27.67
10.08.23
Summary
This prediction ended on 10.08.23 with a price of €27.67. The BUY prediction by efeu finished with a performance of 24.14%. efeu has 50% into this prediction

MorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.

Performance without dividends (%)
Name 1w 1m 1y
MorphoSys AG 1.297% 1.297% 352.848%
iShares Core DAX® 1.883% 5.122% 21.667%
iShares Nasdaq 100 0.125% 2.574% 45.951%
iShares Nikkei 225® -0.201% 4.341% 28.806%
iShares S&P 500 0.728% 4.141% 34.630%

Comments by efeu for this prediction

In the thread Morphosys AG diskutieren
Prediction Buy
Perf. (%) 24.14%
Target price 28.000
Change
Ends at

Die Pipeline macht gute Fortschritte, mit dem Fokus auf dem Alzheimer-Wirkstoff Gantenerumab 

Der Studienerfolg mit dem  Alzheimer-Mittel der US-Firma Biogen strahlt auch auf MorphoSys positiv ab

In the thread Trading Morphosys AG
Prediction Buy
Perf. (%) 24.14%
Target price 28.000
Change
Ends at 09.08.23

Die von efeu gewählte maximale Laufzeit wurde überschritten